Convatec H1 2026 Results Tuesday, 4th August 2026 Disclaimer: This transcript is derived from a recording of the event and has been summarised in certain areas. Every possible effort has been made to transcribe accurately. However, neither Convatec…
Convatec H1 2026
Results
Tuesday, 4th August 2026
Disclaimer: This transcript is derived from a recording of the event and has been summarised
in certain areas. Every possible effort has been made to transcribe accurately. However, neither
Convatec Group plc nor our production partners shall be liable for any inaccuracies, errors, or
omissions. An unmodified version is available from Convatec Investor Relations.
Convatec H1 2026 Results
Tuesday, 4th August 2026
Introduction
Jonny Mason
CEO, Convatec Group
Okay. Good morning, everybody. Nice to see you. Welcome to Convatec’s first half of 2026
results announcements. The usual disclaimers apply.
And today, we’re going to follow the normal format, which is that I’ll give a few words of
introduction, Fiona will talk you through the performance, financial, and outlook, and then I’ll
update on strategic progress before we’ll be happy to take any questions that you’ve got.
Convatec: CMD recap
Let’s start with a quick recap from the Capital Markets Day just back in April. These were the
three things we suggested should be the key takeaways. We operate in large and growing
markets with leading positions. We’re focused on four chronic care categories, which leads to
a high proportion of recurring revenue.
Convatec’s a strong and resilient business. We’re delivering broad-based growth, and we’ve
got a track record of operational improvements, which increase profitability.
And then the
growth opportunity is substantial. We have new products launching across all of those four
categories, which means that we will grow ahead of those growing markets. And there’s more
to come, as you’ll hear today.
The Convatec flywheel
Those structurally growing markets with the leading positions and the recurring revenue, with
our new products launching, that all drives the ConvaTec flywheel. And that’s what leads to
the sustainable level of growth at 6% to 8% for organic revenue and double digits for EPS every
year starting from next year.
And at an operating margin of mid-20s, the cash generation is strong. And that will enable us
to invest organically in opex and capex to sustain the growth, to grow the dividend in line with
earnings, and there will be further capital available to increase returns for shareholders.
On-track delivery, confirming guidance
So that’s what we said in April. And I’m pleased to say that from the first half of this year, we
are on track. We said that faster sales growth would start in 2027, and that 2026 would be
second half-weighted, and that is still how we see it.
In the first half of 2026, revenue growth was good. It was right on track. But in the second
half it will be faster for good reasons, and we’ll get into that.
In the first half, operationally and strategically, our delivery was strong. Our new products are
launching and winning market share.
We are investing across all our four categories in
increasing demand – in increasing capacity, excuse me, to meet the rising demand, and that’s
especially in Infusion Care.
We made good progress on our simplification and productivity initiatives, and that’s what
improves cost efficiency and drives operating margin improvement. And we’re confirming today
that we still expect to reach at least 23% in FY’26.
And that will lead to double-digit EPS
2
Convatec H1 2026 Results
Tuesday, 4th August 2026
growth, the third year in a row of double-digit EPS growth, with strong cash conversion, enough
for the increase in growth capex that we’re deploying this year and to increase the dividend.
And we’re announcing today a share buyback of $200 million. All of that within our target
leverage ratio of 2 times EBITDA.
And then we’re also confirming today that we are on track to deliver our medium-term targets,
which were set out in the Accelerate strategy.
Accelerating from H2 2026
So H2 then. Accelerating. The sales will grow faster in H2, principally because of Infusion Care.
And there, we have high visibility of customer orders. They are uneven but not unpredictable,
and demand is strong. And we also have new products launching in Wound Care and in Ostomy
Care. That’s ConvaFoam and Esteem Body, respectively. And so the growth will build slowly
through the year.
And in Continence Care, we expect the growth from H1 to continue into H2, supported by the
expansion of GC Air for Women and the international growth. So we’re on track to deliver our
FY’26 organic revenue guidance. And today, we’re narrowing the range, which means that for
the second half of the year, growth will be between 6% and 8%.
And then for 2027, we are on track to reach mid-20s in operating margin and for the faster
growth rates of 6% to 8% in sales and double-digit EPS for each year thereafter.
We’ll get into all of that. But for now, let me hand you over to Fiona. I’ll come back shortly.
Financial Review H1 2026
Fiona Ryder
CFO, Convatec Group
H1 26: good performance, on track for FY26
Thank you.
Good morning, everybody.
So I will present a summary of our first half
performance, plus the outlook for the full year before handing back to Jonny for the strategic
review.
We are pleased to report another good financial performance, and we are on track for our fullyear targets. Organic revenue growth, excluding InnovaMatrix, which I’ll talk about shortly,
was 5%, in line with expectations.
Operating margin was 21.2%, down 10 basis points year-on-year, but up 50 basis points at
constant currency. EPS growth was 6%. And we are on track for another year of double-digit
EPS growth.
Free cash flow to equity was lower than last year due to timing effects of working capital and
capex. We still expect around 100% cash conversion for the year. Our interim dividend grew
by 15% as we move towards a one-thirds interim, two-thirds final dividend pattern. We are
still targeting a full-year payout ratio of 35% to 45% of adjusted net profit. And in addition,
this morning, we announced a $200 million share buyback programme to be completed between
now and the year-end.
3
Convatec H1 2026 Results
Tuesday, 4th August 2026
Broad-based organic revenue growth
Revenue growth was again broad-based across all four categories, as this chart demonstrates,
with all four categories contributing materially to sales growth. On the right, you can see the
impact of the significant market uncertainty in skin substitutes.
InnovaMatrix sales decreased $37 million year-on-year to $2.5 million in the first half, which
represented just over 3% headwind to Group revenue growth. And we now estimate full-year
’26 revenue of between $5 million and $10 million, representing a full-year headwind to Group
revenues of about 2.5% and an H2 headwind of about 2%.
As a result of these challenging conditions, we have reduced expectations for the year to
between $5 million to $10 million revenue. And as a result, we’ve taken a non-cash impairment
of $69 million. This means that InnovaMatrix will not have any material negative impact on
our results beyond 2026.
AWC: Growth ahead of market, ConvaFoam building
OC: Esteem Body taking share and ahead of plan
Now let’s look at sales by category, starting with Advanced Wound Care, where sales were up
3.4%, excluding InnovaMatrix.
Overall, markets were a little bit slower than in 2025. And compared with our four-month
trading update, May and June were slightly softer. This was due to some phasing of orders in
Aquacel, which we expect to pick up in the second half.
Advanced Wound Care growth is expected to build in the second half, supported by further
ConvaFoam growth.
In Ostomy Care, organic growth was 4.3%, matching H2 ’25.
The highlight was the
performance of Esteem Body, our one-piece soft convex pouch, which grew ahead of
expectations and is now annualising at around $60 million of revenue and continuing to win
share.
Growth was supported by our updated Esenta accessories range, which is now 20% of Ostomy
Care revenue. Flexi-Seal, which represented about 10% of Ostomy Care, was down 4%, with
fewer intensive care unit procedures due to a less severe flu season than prior year.
We expect Ostomy Care growth to build in the second half, led by Esteem Body scale-up and
new patient starts, and we’re starting to see the early flow of new patients from our recent GPO
wins.
CC: Good H1 growth and increased Convatec mix
IC: Good H1 growth, as expected; H2 to accelerate
In Continence Care, organic growth of 5.9% was driven by further volume increases in the USA,
backed by outstanding customer service and our broadening product portfolio. We saw faster
growth in Convatec product, which is now over 60% of our sales, given our improved portfolio
of products, and faster growth of hydrophilic product, which again was over 60% of revenue.
This included excellent growth in GentleCath Air for Women, which has more than doubled yearon-year and added 1 percentage point to Continence Care growth. We again grew strongly
outside the USA from a low base, and non-US growth contributed over 1 percentage point to
the category growth rate.
4
Convatec H1 2026 Results
Tuesday, 4th August 2026
And then, Infusion Care, where organic growth was 7.4%. There was continued strong demand
in diabetes across both longstanding and newer customers, as the penetration of automated
insulin delivery over multiple daily injections is increasing.
Outside diabetes, growth was again excellent, high double-digit, led by infusion sets for
AbbVie’s Parkinson’s disease treatment. Other therapies represented over 15% of our Infusion
Care revenue, up from about 10% in 2024, with scope to grow further as a share of the
category.
We have a strong position in Infusion Care, with increasing diversity across customers and
products. We expect growth to accelerate in the second half based on visible customer orders,
with double-digit growth in the second half, driving high-single-digit growth for full-year ’26.
H1 26 operating margin: further productivity gains
Moving on to profitability. Operating margin decreased by 10 basis points, but increased by 50
basis points in constant currency. Operations productivity and price and mix improvements
more than offset inflation.
The drop in InnovaMatrix caused 140 basis points drag to operating margin in the first half.
Simplification and productivity initiatives continue to deliver, with commercial and G&A
efficiency adding a further 130 basis points.
Overall, in the first half, opex decreased by 70 basis points as a percentage of revenue to
38.2%. Currency represented a 60 basis points headwind, which is expected to moderate to
40 basis points for the full year based on current spot prices.
H2 operating margin underpinned by higher revenues and strategic initiatives
This slide shows the bridge to higher margin in H2 as part of our at least 23% margin guidance.
This will be driven by four areas. Our H2 revenue is materially higher than H1, as it has been
in previous years. This is driven by customer buying activity and four additional trading days
in the second half versus the first half, which was the same in 2025.
Given that operating expenses are broadly spread throughout the year, this drives an H2 margin
versus H1 of over 200 basis points.
We also have Infusion Care phasing. In the full-year 2026, Infusion Care sales are weighted
towards the second half. This has a positive operational leverage and margin mix effect and
explains a further 50 basis points.
Combined, these factors drive around about 260 basis points margin uplift versus the first half.
For InnovaMatrix, the operating margin drag is lower in the second half ’26. This drives about
40 basis points uplift versus H1.
Lastly, in the second half, there will be further benefits of operational productivity initiatives
started in H2 ’25 and H1 ’26, including automation, strategic sourcing, and debottlenecking,
and this is coupled with specific organisational simplification. These initiatives offset inflation
and are expected to deliver about 80 basis points margin uplift versus H1.
Medium term: on track to deliver mid-20s adjusted operating margin by 2027
This slide shows our margin history, plus a bridge to our mid-term guide of mid-20s margin.
We are on track to deliver this in 2027, driven by a continuation of our productivity initiatives,
5
Convatec H1 2026 Results
Tuesday, 4th August 2026
leverage from 6% to 8% revenue growth, and further opex efficiencies. This is achievable with
inflation at prevailing price levels.
On track for third year of double-digit EPS growth
FY26 EPS growth driven by M/HSD % operating profit growth, lower tax & lower average
share count
Turning to EPS. We are on track for another year of double-digit EPS growth. EPS grew 6% in
the first half and will accelerate in the second half as we benefit from lower interest rates
following our recent refinancing and a lower number of shares in issue following our $300 million
buyback in the second half 2025.
On track for 100% FCFE conversion in FY26, H2 WC inflow expected; capex H1
weighted
On cash, consistent with normal seasonality, net debt increased in the first half. Our capex
programme is advancing well and was first-half weighted. I shall come back to this shortly.
Working capital was higher than the prior year, predominantly due to timing, slightly higher
inventory, timing and mix of trade receivables and payables, and some timing of other accruals
that build through the year.
We expect working capital flow to reverse in the second half, as it does each year. And as such,
we continue to expect around about 100% free cash flow to equity conversion in full-year ’26.
Leverage was 2.3 times at the half year. As you can see on the right-hand side of this chart,
it is usual for leverage to be higher at the half year. Last year was an exception. We expect
to be at about 2 times leverage at the year-end, inclusive of the $200 million share buyback
announced earlier today.
Step up in growth capex; FY guidance unchanged
As you know, we are currently investing significantly to expand capacity to read – to meet rising
market demand. This slide gives some color on the movement year-over-year and the areas
that we are investing in.
We have been busy in the first half with capex H1 weighted.
Our full year guidance is
unchanged. The largest component of the $90 million growth capex was for Infusion Care,
where we are adding significant capacity, in many cases, backed by long-term contracts.
Some new Infusion Care capacity will come on stream later this year, with significantly more in
2027 and beyond. Elsewhere, we are investing to support launches in Advanced Wound Care,
Ostomy Care, and Continence Care, and we expect this growth capex to be accretive to Group
returns.
Operational capex was also H1 weighted, including some IT projects which have now completed.
We continue to expect operational capex to be about 2.5% of revenue for the year.
On track to deliver FY’26 guidance
We are confirming our guidance for full-year ’26. And here’s a summary to help you model.
On operating margin, we continue to expect to reach at least 23%, inclusive of InnovaMatrix
headwinds of about 80 basis points for the full year, and FX headwinds of about 40 basis points.
I would also like to draw your attention to the fact that the legacy Bristol Myers Squibb
amortisation charge ended last month in July, and that was over $95 million annually. And so
6
Convatec H1 2026 Results
Tuesday, 4th August 2026
going forward, that will significantly reduce the difference between our reported and our
adjusted financials.
Financial Summary
In conclusion, we saw a further good financial performance in the first half, and we are on track
to hit our targets. We are investing to underpin faster future growth and returning capital to
our shareholders.
Thank you. I will hand back to Jonny.
Strategic Update
Jonny Mason
CEO, Convatec Group
Four chronic care categories in attractive, structurally growing markets
Thank you very much. So I’ll now say a few words about how we’re getting on implementing
the strategy. And just as a recap, we are very focused in four chronic care categories. And
each one of those is growing because the population is increasing, the population’s aging, and
the prevalence of the diseases which cause the conditions we support is increasing.
Because of the chronic nature of these conditions, it leads to a very high level of recurring
revenue, and that’s a solid and durable foundation for long-term growth.
Accelerate will deliver above-market growth
Now, in each of those categories, we’re going to grow faster than the market by implementing
our Accelerate strategy. Customer growth will be focused, identifying and satisfying unmet
needs. We’ll be investing in R&D to innovate and continue to launch more products. More on
that later in a moment.
We’ll be very focused on execution, cross-functional collaboration, seamless delivery across the
organisation to support the faster growth. And all of this will be underpinned by a strong culture
in the organisation: purpose-led, performance-driven.
You can see on the right of this chart the growth rates for each of the categories. Same as we
announced at the Capital Markets Day. They combine to deliver the faster growth rate at Group
level of 6% to 8% per annum on an ongoing basis.
We have delivered a lot in H1, building to Accelerate
Now, we have been busy in the first half. Wave 1 products are scaling up. Wave 2 products
are progressing well through their launch processes and building on lessons from Wave 1, we
are going at a faster cadence. We are investing in all four categories.
Organic investment in both opex and capex is our top cash allocation priority. And that is, as I
say, building capex – building capacity to support faster growth.
We’re strengthening the
quality in everything we do with an emphasis on right first time.
This is cross-functional
seamless delivery to support the faster growth.
And we’re making good progress on remediating the FDA’s observations regarding our quality
management system. We’re scaling technology. We’re scaling enterprise AI. We’re embedding
7
Convatec H1 2026 Results
Tuesday, 4th August 2026
agentic AI and Copilot across commercial, supply chain operations, financial, which leads to
faster decision-making and measurable productivity improvements.
Simplifying the operating model. Outside of North America and Europe, we’ve been delayering,
which allows for faster decision-making and reduced opex. And we will also be opening our
fourth Convatec Business Services center later this year in India, in Hyderabad, which will focus
on technology and innovation.
And then we are strengthening the leadership team.
Again, this is with a focus on cross-
functional collaboration and delivery of our faster growth.
Wave 1 launches all scaling successfully, except InnovaMatrix. Added over half of
H1 growth
These are our Wave 1 products, and they’re scaling successfully and adding over half of the
organic growth in the first half.
Launched between 2022 and 2025, they provide strong
evidence that our innovation model is working, and that we could successfully bring new
products to market and scale them.
All of these products are in the market and scaling up, except for InnovaMatrix. Now Fiona
spoke a bit about InnovaMatrix just now. The first half was very challenging. The diabetic foot
market – foot ulcer market in particular in the physician’s office is basically frozen at the
moment.
Important point is that this technology works for patients.
The feedback and the evidence
we’ve got is strong, and we expect sales will start to increase slowly in the second half and that
2026 will be the low point with further growth from 2027, but from a very small base.
And going forward, this is going to be just one of our 16 new products contributing to the 6%
to 8% growth at Group level.
It won’t be reported separately, and it will no longer be a
distraction.
From this – for the rest of the list, products such as Mio Advance Extended Wear, ConvaFoam,
infusion sets for diabetes and for Parkinson’s therapies, GentleCath Air and Esteem Body are
scaling well and are gaining market share.
Wave 2 launches progressing
Here are the wave 2 launches, and they’re progressing well.
We’re securing regulatory
approvals, building manufacturing, generating clinical evidence, establishing reimbursement
pathways, and ensuring commercial readiness.
Products are advancing in line with our plans. We’ve got a little key here in the middle of the
chart, these balls, to show the approximate status of each of the launches.
ConvaNiox,
ConvaFiber, and ConvaVAC are in limited market release and customer evaluation.
Cure Aqua, GC Air Pocket & Set are scheduled for launch later this year. The infusion sets for
Tanabe Pharma and for Supernus Parkinson’s treatments are ready to go, pending some
customer approvals. And Natura Body is on schedule for launch next year.
Flexi-Seal Air has been delayed into next year, originally targeted this year, but that’s to
accommodate for some refinements in design following customer evaluation.
Listen, I hope you get a sense from these two slides that there is a lot going on. This is more
than Convatec has ever tried to launch previously, and it’s going really well.
8
Convatec H1 2026 Results
Tuesday, 4th August 2026
ConvaNiox: Creating a new product category
Now, I wanted to share a bit more on two of the products in wave 2, starting with ConvaNiox.
Here, we’re creating an entirely new category in wound care through a multimodal dressing
designed to address multiple barriers to healing simultaneously. The initial focus is diabetic
foot ulcers, where the unmet need is substantial.
Around 16.5 million patients are diagnosed each year, with many wounds failing to heal and
leading to significant costs for the healthcare systems of the order of $10 billion. We have
strong clinical evidence that ConvaNiox works better than the standard of care. The first RCT
demonstrated 60% more ulcers healed within 12 weeks and three times faster wound area
reduction.
We’re continuing to build more evidence with a large US RCT study recruiting ahead of schedule
and results due in 2027. We’re also seeing early encouraging signs of adoption, supported by
regulatory approvals, reimbursement progress, and positive clinician feedback.
Most recently in the UK, we were added to the drug tariff list at a price of £40 per dressing,
which is a very strong proof point of superior performance.
Importantly, we see ConvaNiox as a platform opportunity, not a single product, with potential
to expand into other wound types, including venous leg ulcers, surgical wound complications,
and even into other categories. ConvaNiox will be a strong contributor to growth, not in 2026
or 2027, but we expect it to start to ramp from 2028. And as we’ve previously said, this has
the potential to become our biggest brand.
Parkinson’s: Significant IC opportunity
The second area I wanted to say a bit more on is infusion sets for Parkinson’s disease. This is
an excellent example of diversifying our infusion care category beyond diabetes. Subcutaneous
treatment for Parkinson’s is a relatively new therapy, but it is a growing market with very low
penetration today and a long runway for growth.
In the markets in which we operate, there are four million people with Parkinson’s, and
regrettably, about a million of those have advanced Parkinson’s, requiring continuous
treatment.
Today, around 95% of those advanced Parkinson’s patients are still treated with oral
medication, and only 5% are using pumps.
Oral therapies lead to greater fluctuation in
dopamine on and off periods and can lead to significant patient discomfort.
Pumps provide better treatment.
Breakthroughs like AbbVie’s VYALEV, where we are the
exclusive supplier of infusion sets, are dramatically improving patient outcomes by automating
the Produodopa delivery.
Now, since 2023, pump adoption has grown over 25% CAGR, and we expect it to increase
significantly over time. We’re now supporting additional therapies, including Tanabe Pharma’s
and Supernus’ new treatment. And this creates a really attractive growth opportunity.
Parkinson’s therapies will be a strong underpin of our double-digit growth in Infusion Care going
forward.
9
Convatec H1 2026 Results
Tuesday, 4th August 2026
Three ‘waves’ of product innovation
Now, as we said at the Capital Markets Day in April, we describe our product innovation in three
waves of new products, just for ease of reference. Prior to Wave 1, there were clear gaps in
our product portfolio.
And the Wave 1 launches between 2022 and 2025 substantially
strengthened our competitive position, and those products are now scaling up and delivering
growth.
Wave 2 are the products which are starting to launch now in 2026 and in 2027. And building
on lessons from Wave 1, they are targeting faster growing segments and being delivered
quicker.
Wave 1 and Wave 2 together underpin the acceleration of growth to 6% to 8% for the next
plan period. And then we’ve got Wave 3, which at the moment is in earlier development stage
and will deliver growth in later years.
Future innovation: ‘Wave 3’ highlights
The good news is that these innovations are across all four categories and continuing the theme
of broad-based growth. We’ll say a bit less about Wave 3 at the moment, for obvious reasons,
but it does represent our next horizon of value creation.
The strategy is to maximise our
internal manufacturing capabilities, to leverage the proprietary science across all four categories
and to back it up with clinical validation.
It reflects a deliberate move towards higher growth, stronger differentiation, and attractive new
segments, all of which will represent better economics.
You can see in the center box on this slide the ideas that we have to build on our existing
capabilities and to deliver new and better solutions for users. Predominantly organic, built on
platforms that we have already invested in, but we remain open to external innovation by way
of partnership or deals if they would accelerate our roadmap or help us access new technologies.
So this is all very exciting and ensures the sustainability of our growth model for years to come.
On track to achieve another year of strong growth and continued margin
progression
Now back to 2026. I hope you’ve heard the message that we are on track for another year of
strong growth and margin progression. This will be the fifth consecutive year of sales growth
within our current target range of 5% to 7%, excluding InnovaMatrix. It will be the fifth year
of operating margin expansion, and it will be the third year of double-digit growth in earnings
per share.
Now, as we implement the Accelerate strategy, there is more to come. And we will step up our
sales growth range to 6% to 8% from the second half of this year and thereafter, led by doubledigit growth in Infusion Care.
We’ll reach around 25% operating margin in the second half of this year, and then we will
continue in the mid-20s thereafter. We are very focused on execution, on doing the basics
better, on simplification and productivity, embedding technology and AI tools across the
organisation so that we execute more effectively to accelerate growth.
Summary and outlook
So let me close with three messages. It was a good financial performance in the first half and
strong delivery operationally and strategically. Acceleration is going to begin from the second
10
Convatec H1 2026 Results
Tuesday, 4th August 2026
half of this year. We have good visibility on that, and we are confirming today guidance for
sales, margin, EPS, and cash for 2026 and for the medium-term targets that we announced
previously. And in addition, we’re announcing a $200 million share buyback.
And third, product innovation is going well.
We’re building capacity, which underpins the
sustainable growth of 6% to 8% from 2027, and that will compound to lead to ongoing doubledigit EPS growth and strong cash flow for shareholders.
Thank you very much. We’ll now be happy to take your questions. David, will you coordinate?
Q&A
David Phillips: Sure. Put the mic to Kane at the front, please. If you could hold down the
microphone.
There’s a microphone in the chair.
Just hold the button down and ask your
question.
Kane Slutzkin (Deutsche Bank): Morning. It’s Kane Slutzkin, Deutsche. Just wanted to
know, Jonny, could you touch a bit more on the Wound business, relative to where you were at
the four months? I think you did say something about May and June was quite soft. Just
wondering sort of how should we be viewing that. We’ve obviously seen a few competitors in
recent months with a bit of noise and profit warning. So how should we think about that sort
of European piece? And I guess it’s not as pivotal, I guess you’ve kind of always called it out
as growth is better elsewhere. But just how should we think about it coming down from sort
of mid-single digit 4%? It’s now sort of 3%. Yeah. Just any thoughts on that? Thanks.
Jonny Mason: Sure. Look, the markets in Wound Care have been a bit softer in 2026 than
they were in 2025, about a point around the globe if you look at SmartTRAK.
We’re not
expecting our Wound Care business to be particularly softer for the rest of the year. In fact,
our target growth rate for this year is mid-single digits, and we still expect to achieve that.
May and June was a bit softer than the first four months, but we’re not calling out any particular
reason for that. And what will build our growth in the second half is ConvaFoam launching
stronger. It’s one of the areas where we’re building more capacity. We expect ConvaFoam to
be contributing more and more as the year goes by, and we would still expect to get to midsingle digits for the year.
Kane Slutzkin: Thank you. Just on Infusion Care capacity. I mean, you’ve spoken, I think
sort of even the four-month update demand is sort of outstripping supply. You obviously got
the order phasing, which gives you good visibility.
I’m just wondering what other sort of
execution risk or supply chain risks around that additional capacity that, how sort of nailed on
is the double-digit second half or even post ’26? Just what could go wrong there? Thanks.
Jonny Mason: Yeah. The new capacity really – there’s a bit of it starting to arrive in the second
half of 2026, but not much. Most of it is from 2027 onwards. We’re not reliant on that additional
capacity to deliver double-digit growth in the second half of 2026. For that period, we’ve got
visibility over the orders.
We’ve got the capacity to deliver it.
There is less uncertainty,
obviously, in the nearer term.
From 2027 onwards, look, we – our projects are going well. They’re on target. They’re on
budget. We’re very focused on it. Execution remains, of course, the biggest risk. It has been
11
Convatec H1 2026 Results
Tuesday, 4th August 2026
for years, but it’s going well is what I can say, and we are determined to land that new capacity
in time to meet the rising demand.
Kane Slutzkin: Great. Thanks. Sorry, just sneak one last one in. I just noticed yesterday
that just in light of seeing Supernus up on your – is it Supernus, yeah? Up on your sheet there.
I see they’ve merged with Indivior yesterday. I’m just wondering, have you thought about how
that may open up any new doors, if any, to sort of additional drug device collaboration?
Jonny Mason: I would say it’s a bit early for that. So we haven’t really thought about that
yet.
We’re focused on delivering for both Tanabe Pharma and Supernus.
It’s a great
opportunity that we are the infusion care supplier to all three of the new Parkinson’s treatments.
So as pump therapy – the penetration of pump therapy in that area increases, I guess we’ll
grow with it. Very excited about that.
David Phillips: Let’s go to Hassan in row three and then come across to Jack in the front there.
Hassan Al-Wakeel (Barclays): Morning. Hassan Al-Wakeel from Barclays. I have a couple,
please. So firstly, on opex dynamics. You reduced G&A year-over-year, again, and looked to
have front-loaded R&D in the first half.
I appreciate you’ve talked a lot today about the
confidence you have on the top line with Infusion Care visibility. But can you expand on some
of the opex buffer that you have and some of the productivity improvements planned for the
second half that also support the ramp in profitability?
And then secondly, if you can walk us through what you’re seeing in the skin sub-market with
InnovaMatrix and your confidence in current guidance still seems to be a big step up in the
second half, and how you’re thinking about the pushes and pulls into ’27.
Fiona Ryder: Thanks, Hassan. Well, I’ll take the first one on opex. You’re right, we do continue
to successfully deliver our simplification and productivity initiatives.
They’re both within
operations productivity, where we continue to automate our manufacturing facilities, reduce
bottlenecks, and we have focused on strategic sourcing there.
With regards to G&A, we continue to improve our G&A. As Jonny mentioned, we have just
announced our fourth CBS centre, which will be focused on technology and innovation. We
have done some delayering as well within the organisation. So our second half opex will be
lower than our first half opex in 2026, and our second half opex will be lower than second half
2025.
Jonny Mason: And on skin substitutes, look, the first half was very disappointing. What we
are expecting is for the market to evolve to a new equilibrium. At this lower price that CMS
has set, we can still make decent money, but we think many of the other operators who used
to be in this segment, in particular the human tissue operators, will be very challenged from a
profitability perspective.
What we’re expecting to see is some of the bad actors and also some of the human tissue
operators exiting the market, and the volumes of applications of skin substitutes to reestablish
itself. And our product works really well, as I mentioned in my remarks. So we would expect
volumes to grow. That was the basis of our initial guidance for 2026, and that has not happened
yet. It is happening slower than we thought it would.
12
Convatec H1 2026 Results
Tuesday, 4th August 2026
Two factors I think I’d point to. First is that some of the kind of human tissue operators are
resisting the new price levels, and there are still legal cases going through challenging CMS’s
actions. Now we don’t think that’ll be successful, but it is certainly causing a delay.
And then secondly, CMS are going through some intensive audit activity at the moment to try
and, I guess, root out any inappropriate behavior in the segment. What that’s causing is for
physicians generally to be conducting very low activity.
So that’s why H1 has been
disappointing.
We do think that’ll pass. We’re not sure when. Our sales have started to pick up in the end.
In May and June, they were higher than they were early in the year. It’s slow. We do think
we’ll sell more in the second half than in the first, but we’re not relying on it. We’re managing
our variable costs very tightly. And I think, as I said, the guidance on InnovaMatrix doesn’t
impact the guidance on everything else. It’s now very small. As I say, we do believe in the
product going forward, but it will be so small that it really won’t matter.
Hassan Al-Wakeel: That’s really helpful.
If I could just follow up on the opex dynamics,
particularly as it relates to next year and the buffer that you have there. Jonny, I think when
we spoke a month or two back, you talked about current spot rates for COGS, effectively
pointing to a 6% inflation next year. Where do you see that today, and how could that impact
your plan for 24% margins next year?
Jonny Mason: Since we last spoke – and obviously this is a moving target. The rates are
moving up and down all the time. Since we last spoke, actually, they’ve got a little bit better.
But we haven’t chosen to change the guidance. At prevailing price levels, which is roughly what
they are now, we continue to see inflation would be roughly double next year, and we still think
we can hit our 24% operating margin at that level.
Now, we’ll give more detailed guidance about 2027 when we get closer to the time. But as we
see it today, we’re still on track for that margin progression.
Jack Reynolds-Clark (Morgan Stanley): Hi there. Jack Reynolds-Clark at Morgan Stanley.
Thanks for taking the questions. I had two also, please. First on Niox. That £40 price point
you talked about, how does that compare to what you expected and what do you expect the
gross margin profile to be at that price?
And then on Infusion Care, digging a bit more into the non-diabetes segment, how are your
conversations going with the operators, the non-Parkinson’s partners?
Jonny Mason: Well, I might be a bit elusive on these two. Look, £40, we’re very pleased with.
We see it, as I said, as a very strong demonstration of superior performance. That’s a price
point which is clearly higher, significantly higher than the alternative dressings that we sell and
that other people sell. We don’t get into gross margin by product, and I won’t start that today
either. But at such a nice price point, it’s a profitable product and we’re looking forward to it
growing significantly.
On Infusion Care other therapies, this is really part of our Wave 3. So the double-digit growth,
which underpins our 6% to 8% growth for the Group, can be delivered through diabetes –
growth in diabetes therapies and Parkinson’s therapies. We are talking about other therapies
as you’re referring to, things like immunoglobulin deficiency. I’m blanking.
Fiona Ryder: Pain relief.
13
Convatec H1 2026 Results
Tuesday, 4th August 2026
Jonny Mason: Yeah, pain relief. The cancer one. Chemotherapy. Sorry, I just had a blank.
Chemotherapy. And for those purposes, we are developing infusion sets that can cope with
higher volumes and more viscous solutions.
But they aren’t necessary for the 6% to 8%
growth, and they will be supporting growth thereafter. Still early days, in other words.
Jack Reynolds-Clark: It’s great. Thank you very much.
David Phillips: Seb in the middle, and then we’ll come to Anchal and then Christian.
Seb Jantet (Panmure Gordon): Good morning. Seb Jantet from Panmure Gordon. So a
couple of questions, if I may, or actually one sub-question. IC, just want to talk quickly. You
talk about revenue visibility in the second half. What does that actually mean? Does that mean
firm orders that the kind of customers can’t back out? Does it mean indications of interest, so
on and so forth?
Jonny Mason: It means purchase orders.
Seb Jantet: All right. So it’s locked in, completely locked in?
Jonny Mason: Well, I mean, customers can – if customers phone us up and change their mind,
but they don’t.
Seb Jantet: Yeah.
Jonny Mason: We’ve gone through this pattern for many years recently, and we had the job
of persuading people in 2024 it was going to be second half-weighted, and it was. In 2025, the
job was the opposite. It was higher growth in the first half, and we had to say to people, please
don’t get carried away. It’ll be lower in the second. And it was. Here in 2026, look, we’ve got
the purchase orders.
So we’re confident it’ll be a higher growth rate. It’ll be double-digit growth rate in Infusion
Care in the second half.
Seb Jantet: Okay. Thanks. And then just on the non-diabetes Parkinson’s part of the Infusion
Care business. I’m just wondering to what extent you’ve been able to negotiate more valuebased pricing for your infusion sets there rather than kind of – I mean, I guess what I’m asking
is, are the margins better than the diabetes part of the business?
Jonny Mason: It’s value-based pricing that we pursue with our customers, and these
Parkinson’s therapies are of high value to the healthcare system. And so I think it’s fair to
assume that the margin is good for us, as well as for the supplier of the treatments. So yes.
Seb Jantet: Thank you. And then last question, just on Continence Care. So another really
good kind of period there and strong growth coming outside the US. You’re about to basically
fill out your product portfolio for non-US markets.
Jonny Mason: Yeah.
Seb Jantet: At what point do you decide to actually put your pedal down there and really go
for growth in Europe, expand that business, maybe make some acquisitions to kind of give you
more footprint?
Jonny Mason: Well, our commercial teams would tell you we are putting our foot down. They
feel our foot on their back in strong encouragement. Look, it’s going to be great when we have
GC Air Pocket and Set, which gives our European commercial teams a full kit bag to visit the
14
Convatec H1 2026 Results
Tuesday, 4th August 2026
various urologists’ offices. At the moment, they’re doing an amazing job of driving growth with
one arm tied behind their back.
So we’re looking forward to that very much. That should start to help our growth in Europe
from next year.
So adding a point of growth to the category, we expect that certainly to
continue.
As for acquisitions, look, we’re constantly on the lookout for compelling acquisitions. But the
organic growth is serving us well right now. And I think that our plans are based largely around
that for this next plan period.
David Phillips: Anchal?
Anchal Verma (JP Morgan): Hi. Good morning. Anchal Verma from JP Morgan. Just a few
questions, please. One is on Wound Care, if we can just delve a bit deeper into that. Looking
at the growth ex InnovaMatrix, growth has been, let’s say, closer to the bottom end of the midsingle digit. When we look at the trajectory from here onto high single-digit over the mid-term.
One, is it fair to assume that’s going to be a bit back-end loaded as the new products ramp?
And help us understand how much visibility do you have on that ramp? Let’s say, ConvaFoam,
for example. How much visibility would you have on the orders that have been placed thus
far? And a bit more clarity on that.
When we look at the high single-digit growth, how should we break that up into what’s the
underlying legacy Wound Care business growing at versus the contribution from the new
products?
And then just a short follow-up for Fiona, actually. A bit of clarification on the tariffs. I believe
you did receive some tariff refunds. Are we able to quantify how much of that was booked into
H1, and if there are any more refunds pending for H2?
Jonny Mason: Okay. So let me start with a bit more on Wound Care. Let’s remember that
the wound care category growth is supported principally at the moment by our market-leading
AQUACEL Ag+ Extra product, which, although with a very strong market share, is continuing to
grow really nicely across all of our markets. And that kind of underpins the mid-single digit
growth.
As we move towards high single-digit growth, you asked about the trajectory. Well, it’s – you’re
right to point that out, because we aren’t expecting that to be achieved in 2027. I think what
we’ve said is, in ’27, it will be working its way up mid to high single digits, and then high single
digits from 2028.
Why is that? Because the new product launches will be scaling up all of them by 2028. At the
moment, we’re going through five new product launches in Wound Care. Now the first one’s
InnovaMatrix, which as we all know, has been very disappointing this year, and is a real
exception to the normal pattern. That will start to grow again from ’27 but will be very small.
We’ve got – launching this year, we’ve got ConvaFiber, ConvaVAC, and ConvaNiox. So they
will start to build in ’27 and will really start scaling up in ’28.
ConvaFoam is the one that
launched a couple of years ago, and that is already scaling up now. That’s what we are looking
forward to building in growth through the rest of 2026, and we’re adding capacity for
ConvaFoam accordingly.
15
Convatec H1 2026 Results
Tuesday, 4th August 2026
The buildup curve on that product is really good. You ask about visibility. That’s not something
that you get in Wound Care to the same extent as Infusion Care. As we’ve talked about many
times, in Infusion Care, we get good visibility of orders many months in advance because we’re
talking to a relatively small number of customers.
But in Wound Care and the other categories, of course, you have many, many more customers,
and so the growth builds in a different way.
Fiona Ryder: And on tariffs, we have always said that the tariff impact for us was fairly
immaterial. Most of our products are protected. We did receive a tariff refund in the first half.
Net position, because of course, those tariffs were replaced with new tariffs. So the net tariff
benefit was about $5 million.
Jonny Mason: David?
Chris Glennie (Stifel): Hi. Thanks. Chris Glennie with Stifel. Just the first one on the margin
bridge on our EBIT margin for the second half.
Presumably there are ranges around the
numbers that you put there on the chart. Just if we can tease out a bit of a nuance in terms of
level of confidence in – are they pitched at the sort of bottom end of those ranges, so there’s
strong confidence in delivering that as a minimum? Or is there a bit of stretch in some of those
that you need to hit to deliver that 25% in the second half? Just a bit of a sense for that.
Fiona Ryder: Thank you. I mean, the biggest contributor of the margin growth in the second
half is mechanical. It’s mathematical, and it is simply our sales weighting. We have an extra
four days trading in the second half of the year, and that adds 4%. So that’s the biggest
element of the bridge.
InnovaMatrix headwind won’t exist in the second half to the same extent, so that adds about
40 basis points. That may move up and down a little bit, but it’s so immaterial now.
Infusion Care weighting is in the second half. As we’ve said, we will expect double-digit infusion
care in the second half, which means we’ll be at high single digits for the full year. So Infusion
care adds about 50 basis points. Again, that could move up a little bit, down a little bit, but it’ll
be in the same region.
And lastly, we have delivered our simplification and productivity benefits year-on-year, so I’m
very confident that that will deliver the remaining 80 basis points. So our guidance is at least
23%. We are confident that we will get to 23%.
Chris Glennie: Thank you. That’s clear. And then on maybe any particular – you’re obviously
are not calling out any particular update on the FDA observations, investigations into that
facility. But is there any comment around the intensity maybe of that review from the FDA
side? Is there – and can we have any sense for – I know there’s no formal timelines around
this, but a bit of a sense for when we might reach a sort of conclusion to that?
Jonny Mason: Yeah. Look, it’s going well. We have a constructive relationship with the FDA,
a very open dialogue. And with our customers in InfusionCare – remember, this is an Infusion
Care issue, and the FDA has looked at the whole insulin supply chain. So we’re not the only
one with one of these letters.
So we’re working openly with customers to mitigate the
observations they’ve made.
16
Convatec H1 2026 Results
Tuesday, 4th August 2026
The nature of these things is that they aren’t solved quickly. So we would not expect this to
be lifted anytime soon. It’ll be all the way through 2027 probably. That doesn’t mean it isn’t
going well. It’s just that things take time.
Important to remember, in the meantime, whilst we are improving our quality management
system, there are no observations about patient safety or product quality, and this is not
impacting our ability to manufacture or sell any of our products.
Chris Glennie: Thank you. Sorry, one quick one if you can on ConvaFoam. You talked about
win rate on customer evaluations in the past. I don’t know if there’s any particular update
there, and/or do you have a disclosed growth rate for ConvaFoam in the first half, for example?
Thank you.
Jonny Mason: We haven’t disclosed that particular product, and some of it’s incremental sales
and some of it is replacing our predecessor product.
This is better than our predecessor
product, so that’s good, but I don’t think the growth rate on the product itself would be so
meaningful.
Look, I think ConvaFoam will deliver the mid-single digit growth in Wound Care for the year.
That’s what we are looking for it to do. When we talked about the evaluation rates, that’s when
it was in its early phase of not really selling. So we haven’t updated that stat because we’re
now into a different phase where it’s in the market, it’s scaling up successfully, and it’s doing
really well gaining market share.
David Phillips: Thanks. Charles, and then Sam.
Charles Weston (RBC): Hi. Charles Weston from RBC. Thanks for taking the questions. The
first on Infusion Care, please, in terms of all the capex. Can you give us a sense of how much
additional capacity is being brought online from, say, where we are now to maybe the end of
2028? And as that comes online, is there any pent-up demand that can be satisfied, perhaps
with relation to Tandem?
And then the second question, please, on InnovaMatrix. You said that at the current price you
can make money, but obviously the current volumes are low. So I guess the question is, do
you make money now? And at what stage would you make money? How much more volume
would you need?
Jonny Mason: Okay, great questions. Thank you. Infusion Care, first of all. Look, on Tandem,
I think it’s quite public that we have not managed to keep up with rising demand on certain
SKUs for Tandem. But we have been able to replace those by other SKUs from within our own
range. And so there isn’t a massive impact on sales, albeit we are dissatisfied with not being
able to keep up with what the customer wants, and therefore, in the second half of 2026, we
will be starting to add more capacity to rectify the shortages in those particular SKUs.
On the rest of the capacity, what I think is the best thing to look at is double-digit growth. We
are going to be growing at double-digit growth in the second half of ’26, and then thereafter
for the remainder of the plan period. And the capacity will be sufficient to meet that doubledigit growth for all of those years.
Charles Weston: Just to clarify, does that mean we need more capex at the similar kind of
rate in Infusion Care capacity in ’28, ’29, ’30?
17
Convatec H1 2026 Results
Tuesday, 4th August 2026
Jonny Mason: Yeah. Good clarification. No. We see the capex very much as being at a peak
now, and there will be higher levels next year too, as we adjust to the new growth trajectory.
But then it will settle again to between 5% and 7% of sales on an ongoing basis.
And then on InnovaMatrix – yes, you asked about profitability. Look, we didn’t make money in
the first half. We had controlled our variable costs to what we hoped the sales would be. They
turned out lower. So to Fiona’s point on her margin bridge, we did lose money in the first half.
We think the second half will get back close to breakeven. And then going forward, we need
sales of about $10 million from InnovaMatrix in order to be able to breakeven. And we are
hopeful of getting that and more in the years ahead.
David Phillips: Sam. And then Jens is up. Thanks.
Sam England (Berenberg): Morning, guys. It’s Sam England from Berenberg. Can you talk
a bit about the cadence of product launches during 2027, and how we should think about their
growth contribution next year, given you’re obviously expecting growth to step-up?
And I
suppose, is that around that 50% of growth coming from newer launches like you saw this year,
a sort of realistic prospect for the future?
And then just a quick one around the Wound business. What assumptions are you making
around the underlying market growth in the second half of this year, given you’re expecting an
acceleration? So if we sort of ignore the new products and what’s going on for you specifically,
what are you thinking the market’s going to do second half?
Jonny Mason: Yeah. 2027 will see fewer new product launches than 2026. We have got
scheduled six new product launches in 2026, albeit these things aren’t a fixed event on one
day. They are a gradual process, but they’ll be starting in 2026. Then only two in 2027 is the
schedule, which is Natura Body around the middle of the year. Very important launch, that
one. Very keen to get that into the portfolio. And then FMS Air is a much smaller launch.
That’ll be probably towards the end of next year by the time we’ve optimised the design.
2027 is going to be a year mostly of scaling up the Wave 2 products, which have launched –
which have started launching in 2026. And will that account for about half of the growth? I
expect it’ll be pretty similar to this year. Yeah.
And then on Wound Care, we’re expecting the market to be roughly the same as the first half.
Our expectation of faster growth in the second half is not based on a faster market, but it’s
more based on ConvaFoam contributing stronger as we build, including building more capacity.
David Phillips: Jens?
Jens Lindqvist (Investec): Yeah. Jens Lindqvist at Investec. Appreciate it is a bit blue sky,
bit on foam, what do you see is the long-term potential share of this product? I mean, 30%
share in antimicrobial. Is there any particular reason you would not be able to get towards that
sort of level over time?
And secondly on, what’s your optionality around InnovaMatrix? Is there a non-US opportunity
for that product, and is it really still core or would you consider licensing it or divesting it?
Thank you.
Jonny Mason: Thank you, Jens. ConvaFoam, I love your ambition. Yeah, certainly it can grow
for quite some way. I think what you’re referring to is the fact that with Aquacel, where we
18
Convatec H1 2026 Results
Tuesday, 4th August 2026
have a market-leading product, we have 30% share. In the foam segment, which is around $2
billion, we have a five – we used to have a 5% share. Now that’s grown to over 6% on the
basis of the initial ConvaFoam launch.
Our ambition, our first target is to get the foam share from 5% to 10%. That’s what we’ve got
our sights set on.
Now can it go beyond that? Well, it’s the same people and the same customers that we’re
selling to as for Aquacel. Can it go beyond 10% market share? Maybe. But let’s get to 10
first, and then we’ll see.
In terms of InnovaMatrix optionality, look, we are diversifying the indications and channels that
we are using to sell InnovaMatrix. Previously, it was principally diabetic foot ulcers and venous
leg ulcers in physicians’ offices.
Already this year in the US, we’re looking more at Mohs
surgery, at dermatology, maybe some burns units. So there is optionality in InnovaMatrix, yes.
Is there opportunity to launch it outside the US? Yes, there is. And we’ve started very slowly,
a bit in LATAM, a bit in Europe. But it’s small. That’s our main point. And the key thing about
InnovaMatrix going forward from 2026 is we believe it will grow.
We believe it’s a good
technology as demonstrated by the evidence, but it’s going to be small, and it’s no longer going
to be a distraction. It will be one product among many, contributing to our 6% to 8% growth
rate.
David Phillips: There are no questions online or on the phone. So if there’s no more in the
room, I’ll hand back to Jonny.
Jonny Mason: Well, thank you very much. Thank you for your attention today. You know
where we are if you have any more questions. I hope you’ve got the message today that we
are feeling quite upbeat. I realise there’s some skepticism around will we get to 2026? What
it reminds me of is, back in 2024, when we were at the half year point and our earnings per
share were flat and people said, Oh, you’re not going to get to double-digit EPS growth in 2026
– in 2024, excuse me. Yes, we are. We had good visibility of it, and sure enough, we did. And
That’s how 2026 will be, too.
We have good visibility over the second half of the year. We’re feeling confident we’ll get where
we’ve guided, and that that will form a very strong base for the acceleration in 2027 and
beyond. Thank you very much.
[END OF TRANSCRIPT]
19